Edwards Lifesciences price target raised to $95 from $92 at UBS

UBS raised the firm’s price target on Edwards Lifesciences to $95 from $92 and keeps a Neutral rating on the shares. Edwards’s Q1 results were slightly above expectations with 10% constant currency sales growth, and UBS came away from the call with little to shake its confidence in the company’s ability to achieve its current 8%-10% global Transcatheter Aortic Valve Replacement sales growth guidance, the analyst tells investors in a research note. UBS views this quarter as supportive of the view that Edwards can sustain a high single digit/low double digit sales growth rate, but the firm is still searching for conviction in upside to this target.